Login to Your Account



Sygnis Pulls in $24M in Rights Offering for Stroke Drug Trial

By Cormac Sheridan


Wednesday, October 22, 2008
Underlining the value of having big backers in these straitened times, Sygnis Pharma AG unveiled an €18.3 million (US$24.4 million) rights offering that already is fully backed by its two largest shareholders. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription